Oncolytic virotherapy with an armed vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tumor microenvironment.

abstract：:In the context of a Phase I clinical trial, the long-term vaccination of advanced biliary tract cancer patients with peptides derived from four distinct cancer-testis antigens resulted in remarkable disease stability and in the elicitation of antigen-specific T-cell responses. ...

journal_title：Oncoimmunology

authors： Aruga A

更新日期：2013-07-01 00:00:00

abstract：:Immunotherapy with immune checkpoint molecule-specific monoclonal antibody have obtained encouraging results from preclinical studies and clinical trials, which promoted us to explore whether this kind of immunotherapy could be applicable to head and neck squamous cell carcinoma (HNSCC). Lymphocyte activation gene-3 (...

journal_title：Oncoimmunology

authors： Deng WW,Mao L,Yu GT,Bu LL,Ma SR,Liu B,Gutkind JS,Kulkarni AB,Zhang WF,Sun ZJ

更新日期：2016-10-07 00:00:00

abstract：:We have previously reported a novel phenotype of myeloid suppressors in lymphoma patients characterized by a loss of HLA-DR expression on monocytes, CD14+HLA-DRlow/neg. These cells were directly immunosuppressive and were associated with poor clinical outcome. In this study, we found that lymphoma tumors could have mo...

journal_title：Oncoimmunology

authors： Zhang ZJ,Bulur PA,Dogan A,Gastineau DA,Dietz AB,Lin Y

更新日期：2015-01-26 00:00:00

abstract：:Prolonged lymphopenia correlating with decreased survival commonly occurs among glioma patients undergoing radiation therapy (RT) and temozolomide (TMZ) treatment. To better understand the pathophysiology of this phenomenon, we prospectively monitored serum cytokine levels and lymphocyte subsets in 15 high-grade gliom...

journal_title：Oncoimmunology

authors： Ellsworth S,Balmanoukian A,Kos F,Nirschl CJ,Nirschl TR,Grossman SA,Luznik L,Drake CG

更新日期：2014-01-01 00:00:00

abstract：:The generation and loading of dendritic cells (DC) ex-vivo for tumor vaccination purposes is laborious and costly. Direct intradermal (i.d.) administration of tumor-associated antigens could be an attractive alternative approach, provided that efficient uptake and cross-presentation by appropriately activated skin DCs...

journal_title：Oncoimmunology

authors： Ruben JM,Bontkes HJ,Westers TM,Hooijberg E,Ossenkoppele GJ,van de Loosdrecht AA,de Gruijl TD

更新日期：2014-07-03 00:00:00

abstract：:Tumors arise and progress in immunocompetent hosts presumably by activating tolerance mechanisms critical for normal homeostasis. Host immune cells can mount anti-tumor responses by activation of Toll-like receptors (TLRs). However, emerging data suggests that molecules that negatively regulate TLRs are exploited by t...

journal_title：Oncoimmunology

authors： Standiford TJ,Keshamouni VG

更新日期：2012-05-01 00:00:00

abstract：:Vaccines designed to abrogate the tolerance of tumor self-antigens and amplify cytotoxic CD8+ T cells (CTLs) have promise for the treatment of cancer. Type I natural killer (NKT) cells have attracted considerable interest in the cancer therapy field. In the current study, we have exploited the unique ability of NKT ce...

journal_title：Oncoimmunology

authors： Ghinnagow R,De Meester J,Cruz LJ,Aspord C,Corgnac S,Macho-Fernandez E,Soulard D,Fontaine J,Chaperot L,Charles J,Soncin F,Mami-Chouaib F,Plumas J,Faveeuw C,Trottein F

更新日期：2017-08-18 00:00:00

abstract：:In many cancers, regulatory T cells (Treg) play a crucial role in suppressing the effector immune response thereby permitting tumor development. Indeed, in mouse models, their depletion can promote the regression of tumors of various origins, including renal cell carcinoma when located subcutaneous (SC). In the presen...

journal_title：Oncoimmunology

authors： Devaud C,Westwood JA,Teng MW,John LB,Yong CS,Duong CP,Smyth MJ,Darcy PK,Kershaw MH

更新日期：2014-12-21 00:00:00

abstract：:TRAF2 dependent K63-polyubiquitinations have been recently shown to connect CD137 (4-1BB) stimulation to NF-κB activation. In a search of deubiquitinase enzymes (DUBs) that could regulate such a signaling route, A20 and CYLD were found to coimmunoprecipitate with CD137 and TRAF2 complexes. Indeed, overexpression of A2...

journal_title：Oncoimmunology

authors： Azpilikueta A,Bolaños E,Lang V,Labiano S,Aznar MA,Etxeberria I,Teijeira A,Rodriguez-Ruiz ME,Perez-Gracia JL,Jure-Kunkel M,Zapata JM,Rodriguez MS,Melero I

更新日期：2017-09-21 00:00:00

abstract：:Tumor cells expressing TLRs is generally recognized to mediate tumor inflammation. However, whether and how tumor TLR signaling pathways negatively regulate tumor inflammation remains unclear. In this report, we find that TLR4 signaling of H22 hepatocarcinoma tumor cells is transduced through MyD88 pathway to actin cy...

journal_title：Oncoimmunology

authors： Li D,Jia H,Zhang H,Lv M,Liu J,Zhang Y,Huang T,Huang B

更新日期：2012-08-01 00:00:00

abstract：:The immune system avoids oncogenesis and slows down tumor progression through a mechanism called immunosurveillance. Nevertheless, some malignant cells manage to escape from immune control and form clinically detectable tumors. Tetraploidy, which consists in the intrinsically unstable duplication of the genome, is con...

journal_title：Oncoimmunology

authors： Aranda F,Chaba K,Bloy N,Garcia P,Bordenave C,Martins I,Stoll G,Tesniere A,Kroemer G,Senovilla L

更新日期：2018-05-21 00:00:00

abstract：:Removal of immuno-suppression has been reported to enhance antitumor immunity primed by checkpoint inhibitors. Although PD-1 blockade failed to control tumor growth in a transgenic murine neuroblastoma model, concurrent inhibition of colony stimulating factor 1 receptor (CSF-1R) by BLZ945 reprogrammed suppressive myel...

journal_title：Oncoimmunology

authors： Eissler N,Mao Y,Brodin D,Reuterswärd P,Andersson Svahn H,Johnsen JI,Kiessling R,Kogner P

更新日期：2016-09-09 00:00:00

abstract：:Interleukin (IL)-10 is a major cancer-related immunosuppressive factor, exhibiting a unique ability to hamper the maturation of dendritic cells (DCs). We have previously reported that IL-10 induces the conversion of activated, migratory CD1a+ DCs found in the human skin to CD14+CD141+ macrophage-like cells. Here, as a...

journal_title：Oncoimmunology

authors： Lindenberg JJ,van de Ven R,Lougheed SM,Zomer A,Santegoets SJ,Griffioen AW,Hooijberg E,van den Eertwegh AJ,Thijssen VL,Scheper RJ,Oosterhoff D,de Gruijl TD

更新日期：2013-04-01 00:00:00

abstract：:Prostate cancer (PCa) was estimated to have the second highest global incidence rate for male non-skin tumors and is the fifth most deadly in men thus mandating the need for novel treatment options. MG1-Maraba is a potent and versatile oncolytic virus capable of lethally infecting a variety of prostatic tumor cell lin...

journal_title：Oncoimmunology

authors： Atherton MJ,Stephenson KB,Tzelepis F,Bakhshinyan D,Nikota JK,Son HH,Jirovec A,Lefebvre C,Dvorkin-Gheva A,Ashkar AA,Wan Y,Stojdl DF,Belanger EC,Breau RH,Bell JC,Saad F,Singh SK,Diallo JS,Lichty BD

更新日期：2018-03-27 00:00:00

abstract：:Immunotherapy by chimeric antigen receptor (CAR)-modified T-cells has shown unprecedented clinical efficacy for hematological malignancies. Recently two CAR T-cell based therapeutics, Kymriah (Tisagenlecleucel) and Yescarta (Axicabtagene ciloleucel) were approved by the US Food and Drug Administration and by the Europ...

journal_title：Oncoimmunology

authors： Alcantara M,Du Rusquec P,Romano E

更新日期：2020-06-10 00:00:00

abstract：:Human papillomavirus (HPV) infection is one of the most important etiologic causes of oropharyngeal head and neck squamous cell carcinoma (HNSCC). Patients with HPV-positive HNSCC were reported to have a better clinical outcome than patients with HPV-negative cancers. However, little is known about the possible causes...

journal_title：Oncoimmunology

authors： Partlová S,Bouček J,Kloudová K,Lukešová E,Zábrodský M,Grega M,Fučíková J,Truxová I,Tachezy R,Špíšek R,Fialová A

更新日期：2015-01-30 00:00:00

abstract：:In recent years, bispecific antibodies (bsAb) have emerged as promising tools for a target-specific redirection of T cells in order to eliminate malignant cells. However, CD3-engaging constructs might also activate T regulatory cells (Tregs) present in the tumor microenvironment. Whether this has detrimental or benefi...

journal_title：Oncoimmunology

authors： Koristka S,Cartellieri M,Arndt C,Feldmann A,Seliger B,Ehninger G,Bachmann MP

更新日期：2015-01-23 00:00:00

abstract：:Despite the clinical success of anti-PD1 antibody (α-PD1) therapy, the immune mechanisms contributing to the antineoplastic response remain unclear. Here, we describe novel aspects of the immune response involved in α-PD1-induced antitumor effects using an orthotopic Kras (G12D)/p53(R172H)/Pdx1-Cre (KPC) model of panc...

journal_title：Oncoimmunology

authors： D'Alincourt Salazar M,Manuel ER,Tsai W,D'Apuzzo M,Goldstein L,Blazar BR,Diamond DJ

更新日期：2016-03-16 00:00:00

abstract：:The recent findings on NK activation indicate that these cells are important antitumor effectors. NK cells participate in the graft-vs.-leukemia effect to control the relapse in leukemic patients transplanted with allogeneic hematopoietic stem cells. In various tumors, correlation between NK cell infiltrates and progn...

journal_title：Oncoimmunology

authors： Fregni G,Perier A,Avril MF,Caignard A

更新日期：2012-01-01 00:00:00

abstract：:Vaccines in combination with chemotherapy have been shown to be safe in different tumor types. We investigated the immunological activity of the TroVax® vaccine in combination with pemetrexed-cisplatin chemotherapy in malignant pleural mesothelioma (MPM). In this first line, open-label, single-arm, phase 2 study, pati...

journal_title：Oncoimmunology

authors： Lester JF,Casbard AC,Al-Taei S,Harrop R,Katona L,Attanoos RL,Tabi Z,Griffiths GO

更新日期：2018-09-07 00:00:00

abstract：:Both genetic and environmental factors are thought to be causal in gliomagenesis. Several genes have been implicated in glioma development, but the putative role of a major immunity-related gene complex member, immunoglobulin heavy chain γ (IGHG) has not been evaluated. Prior observations that IGHG-encoded γ marker (G...

journal_title：Oncoimmunology

authors： Pandey JP,Kaur N,Costa S,Amorim J,Nabico R,Linhares P,Vaz R,Viana-Pereira M,Reis RM

更新日期：2014-05-23 00:00:00

abstract：:By analyzing CD4+ lymphocytes in human breast carcinomas, we have recently uncovered the presence of follicular helper T cells in lesions exhibiting an extensive immune infiltrate. The presence of these specialized CD4+ T cells, which localize to the germinal centers of peritumoral tertiary lymphoid structures found i...

journal_title：Oncoimmunology

authors： Gu-Trantien C,Willard-Gallo K

更新日期：2013-10-01 00:00:00

abstract：:Although anticancer therapy with immune checkpoint blockers has seen unprecedented success, it fails to control neoplasia in most patients and often causes immune-related adverse events (irAEs). Our recent research shows the immunostimulatory and antitumor effects of CTLA-4 blockade depend on distinct Bacteroides spec...

journal_title：Oncoimmunology

authors： Pitt JM,Vétizou M,Gomperts Boneca I,Lepage P,Chamaillard M,Zitvogel L

更新日期：2016-02-18 00:00:00

abstract：:Natural killer (NK)-cell count is predictive of chronic lymphoid leukemia (CLL) disease progression and their dysfunction is well documented, but the etiology of this is currently lacking. CLL cells have been shown to over-express HLA-E, the natural ligand for NKG2A expressed on NK-cells that generates a distinct nega...

journal_title：Oncoimmunology

authors： McWilliams EM,Mele JM,Cheney C,Timmerman EA,Fiazuddin F,Strattan EJ,Mo X,Byrd JC,Muthusamy N,Awan FT

更新日期：2016-09-09 00:00:00

abstract：:The metabolic gene isocitrate dehydrogenase 1 (IDH1) is commonly mutated in lower grade glioma (LGG) and secondary glioblastoma (GBM). Regulatory T cells (Tregs) play a significant role in the suppression of antitumor immunity in human glioma. Given the importance of Tregs in the overall framework of designing immune-...

journal_title：Oncoimmunology

authors： Richardson LG,Nieman LT,Stemmer-Rachamimov AO,Zheng XS,Stafford K,Nagashima H,Miller JJ,Kiyokawa J,Ting DT,Wakimoto H,Cahill DP,Choi BD,Curry WT

更新日期：2020-08-20 00:00:00

abstract：:Checkpoint inhibition has established immunotherapy as a major modality of cancer treatment. However, the success of cancer immunotherapy is still limited as immune regulation of tumor immunity is very complicated and mechanisms involved may also differ among cancer types. Beside checkpoints, other good candidates for...

journal_title：Oncoimmunology

authors： Terabe M,Robertson FC,Clark K,De Ravin E,Bloom A,Venzon DJ,Kato S,Mirza A,Berzofsky JA

更新日期：2017-03-31 00:00:00

abstract：:A non-antigen specific immunotherapy consisting of repeated co-administration of poly-IC and blocking antibodies targeting the programmed cell death-1 (PD-1) pathway dramatically inhibits tumor development in several mouse models of cancer. Tumor-reactive CD8+ T cells mediate the antitumor effects mediated by PD-1 blo...

journal_title：Oncoimmunology

authors： Nagato T,Celis E

更新日期：2014-05-15 00:00:00

abstract：:The achievement of malignant traits in several cancers is associated with tumor microenvironment reactivity. New evidence show that the stress hormone noradrenaline enhances melanoma microenvironment reactivity, mainly acting through β3-adrenoreceptors (β2-ARs), favoring recruitment of cancer-associated fibroblasts, M...

journal_title：Oncoimmunology

authors： Chiarugi P,Filippi L

更新日期：2015-04-02 00:00:00

abstract：:Cancer immunotherapy continues to make headway as a treatment for advanced stage tumors, revealing an urgent need to understand the fundamentals of anti-tumor immune responses. Noteworthy is a scarcity of data pertaining to the breadth and specificity of tumor-specific T cell responses in metastatic breast cancer. Aut...

journal_title：Oncoimmunology

authors： DeVette CI,Gundlapalli H,Lai SA,McMurtrey CP,Hoover AR,Gurung HR,Chen WR,Welm AL,Hildebrand WH

更新日期：2019-11-29 00:00:00

abstract：:VXM01 is a first-in-kind orally applied tumor vaccine based on live attenuated Salmonella typhi carrying an expression plasmid encoding VEGFR2, an antigen expressed on tumor vasculature and a stable and accessible target for anti-angiogenic intervention. A recent randomized, placebo-controlled, phase I dose-escalation...

journal_title：Oncoimmunology

authors： Schmitz-Winnenthal FH,Hohmann N,Schmidt T,Podola L,Friedrich T,Lubenau H,Springer M,Wieckowski S,Breiner KM,Mikus G,Büchler MW,Keller AV,Koc R,Springfeld C,Knebel P,Bucur M,Grenacher L,Haefeli WE,Beckhove P

更新日期：2018-01-16 00:00:00